Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARA American Renal Associates	$11.52	$11.50	$5.57 ▼ $11.98	$397.94M	1.11	106,940 shs	9,831 shs
CDTX Cidara Therapeutics	$67.49 +3.8%	$52.82	$10.14 ▼ $69.36	$1.65B	1.18	425,657 shs	661,938 shs
TVTX Travere Therapeutics	$17.79 -1.0%	$15.98	$8.46 ▼ $25.29	$1.60B	0.74	1.54 million shs	1.05 million shs
TXG 10x Genomics	$13.10 -1.9%	$12.46	$6.78 ▼ $24.76	$1.66B	2.03	3.46 million shs	2.08 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARA American Renal Associates	0.00%	0.00%	0.00%	0.00%	0.00%
CDTX Cidara Therapeutics	+5.76%	+2.81%	+13.99%	+153.04%	+402.16%
TVTX Travere Therapeutics	+1.93%	-0.44%	+13.59%	+14.46%	+101.91%
TXG 10x Genomics	-0.37%	-1.55%	+15.77%	+56.44%	-40.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.5373 of 5 stars	2.6	3.0	0.0	4.6	2.2	1.7	0.0
TVTX Travere Therapeutics	2.5868 of 5 stars	3.4	3.0	0.0	0.0	2.8	0.8	0.6
TXG 10x Genomics	3.7007 of 5 stars	2.2	2.0	0.0	4.8	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARA American Renal Associates	0.00	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-4.96% Downside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.21	81.08% Upside
TXG 10x Genomics	2.38	Hold	$13.54	3.37% Upside

Current Analyst Ratings Breakdown

Latest ARA, CDTX, TVTX, and TXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	TXG 10x Genomics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
8/12/2025	TXG 10x Genomics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $17.00
8/11/2025	TXG 10x Genomics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$16.00
8/10/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	TXG 10x Genomics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $13.00
8/8/2025	TXG 10x Genomics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$14.00
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/8/2025	TXG 10x Genomics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$13.00 ➝ $15.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARA American Renal Associates	$822.52M	0.48	$1.69 per share	6.80	$2.59 per share	4.45
CDTX Cidara Therapeutics	$1.27M	1,347.67	N/A	N/A	$19.76 per share	3.42
TVTX Travere Therapeutics	$233.18M	6.80	N/A	N/A	$0.37 per share	48.08
TXG 10x Genomics	$610.78M	2.67	N/A	N/A	$6.21 per share	2.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARA American Renal Associates	-$13.79M	$0.26	N/A	N/A	N/A	-2.04%	-3.56%	-0.24%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-717.68%	-30.69%	10/30/2025 (Estimated)
TXG 10x Genomics	-$182.63M	-$0.70	N/A	N/A	N/A	-13.13%	-12.88%	-10.03%	10/27/2025 (Estimated)

Latest ARA, CDTX, TVTX, and TXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	TXG 10x Genomics	-$0.35	$0.28	+$0.63	$0.28	$139.36 million	$172.91 million
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARA American Renal Associates	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARA American Renal Associates	7.54	1.05	1.02
CDTX Cidara Therapeutics	N/A	16.45	16.45
TVTX Travere Therapeutics	9.50	2.00	1.98
TXG 10x Genomics	N/A	5.84	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARA American Renal Associates	78.42%
CDTX Cidara Therapeutics	35.82%
TVTX Travere Therapeutics	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
ARA American Renal Associates	9.50%
CDTX Cidara Therapeutics	3.89%
TVTX Travere Therapeutics	4.19%
TXG 10x Genomics	9.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARA American Renal Associates	4,977	34.54 million	N/A	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
TVTX Travere Therapeutics	460	89.14 million	85.40 million	Optionable
TXG 10x Genomics	1,240	124.49 million	112.80 million	Optionable

ARA, CDTX, TVTX, and TXG Headlines

Recent News About These Companies

10x Genomics Earns Relative Strength Rating Upgrade; Hits Key Benchmark

August 21 at 1:57 PM | msn.com

2 Growth Stocks Cathie Wood Is Buying Non-Stop

August 21 at 10:26 AM | 247wallst.com

Cathie Wood’s ARK Investment buys 468K shares of 10x Genomics today

August 20 at 2:07 AM | msn.com

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and ...

August 19 at 10:11 AM | gurufocus.com

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and ...

August 19 at 9:31 AM | gurufocus.com

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

August 19 at 9:00 AM | prnewswire.com

10x Genomics' (TXG) "Sell (E+)" Rating Reiterated at Weiss Ratings

August 16, 2025 | marketbeat.com

10x Genomics (NASDAQ:TXG) Stock Price Up 10.6% - Still a Buy?

August 15, 2025 | marketbeat.com

10x Genomics’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 14, 2025 | finance.yahoo.com

FMR LLC Increases Stake in 10x Genomics Inc: A Strategic Move Amidst Undervaluation

August 14, 2025 | gurufocus.com

10x Genomics (NASDAQ:TXG) Given Consensus Rating of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

Leerink Partners Remains a Hold on 10x Genomics (TXG)

August 13, 2025 | theglobeandmail.com

J.P. Morgan Remains a Hold on 10x Genomics (TXG)

August 13, 2025 | theglobeandmail.com

10x Genomics (NASDAQ:TXG) Price Target Lowered to $17.00 at Morgan Stanley

August 13, 2025 | marketbeat.com

Earnings Beat: 10x Genomics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 13, 2025 | finance.yahoo.com

Morgan Stanley Lowers 10x Genomics (NASDAQ:TXG) Price Target to $17.00

August 13, 2025 | americanbankingnews.com

10X Genomics Balances Growth and Challenges in Earnings Call

August 13, 2025 | msn.com

10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by Analysts

August 13, 2025 | americanbankingnews.com

TXG Q2 Deep Dive: Robust Product Demand and Cautious Outlook Amid Funding Uncertainty

August 11, 2025 | finance.yahoo.com

10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.63 EPS

August 11, 2025 | marketbeat.com

5 Must-Buy Efficient Stocks to Buy Amid Volatile Market Conditions

August 11, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARA, CDTX, TVTX, and TXG Company Descriptions

American Renal Associates NYSE:ARA

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Cidara Therapeutics NASDAQ:CDTX

$67.49 +2.46 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$68.24 +0.75 (+1.11%)

As of 07:59 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Travere Therapeutics NASDAQ:TVTX

$17.79 -0.18 (-1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$17.79 0.00 (0.00%)

As of 07:46 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

10x Genomics NASDAQ:TXG

$13.10 -0.26 (-1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$13.22 +0.13 (+0.95%)

As of 07:55 PM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time